Nefopam hydrochloride loaded microspheres for post-operative pain management: synthesis, physicochemical characterization andin-vivoevaluation
Source abstract
Abstract
Once-daily oral dosage of nefopam hydrochloride loaded sustained release microspheres (NPH-MS) was investigated as novel therapeutic strategy for post-operative pain management. Microspheres were synthesized using poly-3-hydroxybutyrate and poly-(ɛ-caprolactone) by double emulsion solvent evaporation technique. NPH-MS were characterized through FTIR, PXRD and SEM. In-vitro drug release study revealed sustained behavior till 24 h. Haemolysis was <5% which signified haemocompatibility of formulation. ED50 in rat tail-flick anti-nociceptive test was found ∼18.12 mg/kg. In post-operative pain model, reversal of mechanical allodynia and thermal hyperalgesia by NPH-MS was statistically significant (p < .001) as compared with NPH till 24 h post-dose.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Pain Mechanisms and Treatments · Advancements in Transdermal Drug Delivery · Anesthesia and Pain Management
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Chitkara College of Pharmacy, Chandigarh-Patiala National Highway, Rajpura, Patiala, Punjab, India;
Department of Research, Innovation and Consultancy, IKG Punjab Technical University, Jalandhar-Kapurthala Highway, Kapurthala, Punjab, India;
Chandigarh College of Pharmacy, Landran, Kharar, Punjab, India
References (31)
Show source-provided references
1. 10.2147/IJN.S59610.2147/IJN.S596 ↗
2. 10.1034/j.1600-0773.2003.920605.x10.1034/j.1600-0773.2003.920605.x ↗
3. 10.3344/kjp.2014.27.2.10310.3344/kjp.2014.27.2.103 ↗
4. 10.1016/j.colsurfb.2009.08.00310.1016/j.colsurfb.2009.08.003 ↗
5. 10.1002/jbm.a.1029710.1002/jbm.a.10297 ↗
6. 10.1016/S0032-3861(99)00534-010.1016/S0032-3861(99)00534-0 ↗
7. Marin E · Int J Nanomedicine · 2013 · 8 · 3071
8. 10.1016/S0142-9418(01)00142-810.1016/S0142-9418(01)00142-8 ↗
9. 10.1016/j.ijpharm.2004.01.04410.1016/j.ijpharm.2004.01.044 ↗
10. 10.1080/02652049928878010.1080/026520499288780 ↗
11. 10.3390/ijms1207429410.3390/ijms12074294 ↗
12. 10.1016/j.jscs.2011.11.00410.1016/j.jscs.2011.11.004 ↗
13. 10.1186/s40199-014-0087-010.1186/s40199-014-0087-0 ↗
14. 10.1002/jps.2226610.1002/jps.22266 ↗
15. D’Souza S. · Adv Pharm · 2014 · 2014 · 1
16. 10.1007/s12645-013-0037-410.1007/s12645-013-0037-4 ↗
17. Singh S · Nanomedicine (Lond) · 2007 · 3 · 305
18. 10.1016/S0928-0987(01)00095-110.1016/S0928-0987(01)00095-1 ↗
19. 10.3109/10717544.2014.93698810.3109/10717544.2014.936988 ↗
20. Brady LS · J Pharmacol Exp Ther · 1982 · 222 · 19010.1016/S0022-3565(25)33172-1 ↗
21. D’Amour FE · J Pharmacol Exp Ther · 1941 · 72 · 7410.1016/S0022-3565(25)03823-6 ↗
22. 10.1124/jpet.104.07596010.1124/jpet.104.075960 ↗
23. 10.1016/0304-3959(95)01441-110.1016/0304-3959(95)01441-1 ↗
24. 10.1016/j.jpain.2009.01.00310.1016/j.jpain.2009.01.003 ↗
25. 10.1093/bja/aes30210.1093/bja/aes302 ↗
26. 10.1038/sj.bjp.070556810.1038/sj.bjp.0705568 ↗
27. 10.1007/s00221000063010.1007/s002210000630 ↗
28. 10.1016/0304-3959(88)90026-710.1016/0304-3959(88)90026-7 ↗
29. 10.1097/00000542-199903000-0003010.1097/00000542-199903000-00030 ↗
30. 10.3109/03639045.2012.68105410.3109/03639045.2012.681054 ↗
31. 10.1016/S0928-0987(03)00048-410.1016/S0928-0987(03)00048-4 ↗